{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:35:24Z","timestamp":1792175724365,"version":"4.4.0"},"reference-count":144,"publisher":"IOP Publishing","issue":"1","license":[{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/page\/copyright"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/iopscience.iop.org\/info\/page\/text-and-data-mining"}],"funder":[{"name":"National Center for Nanoscience and Technology of China"},{"name":"Royal Thailand Government-UCAS Scholarship"},{"name":"The National Key Research & Development Program of China","award":["2021YFA1201000"],"award-info":[{"award-number":["2021YFA1201000"]}]},{"DOI":"10.13039\/501100011332","name":"University of Chinese Academy of Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011332","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Natural Science Foundation of China (NSFC) International Collaboration","award":["51861135103"],"award-info":[{"award-number":["51861135103"]}]},{"name":"NSFC Key Project","award":["32030060"],"award-info":[{"award-number":["32030060"]}]},{"name":"Science Fund for Creative Research Groups of Nature Science Foundation of Hebei Province","award":["B2021201038"],"award-info":[{"award-number":["B2021201038"]}]},{"DOI":"10.13039\/501100004283","name":"Office of the Civil Service Commission","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004283","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["iopscience.iop.org"],"crossmark-restriction":false},"short-container-title":["Prog. Biomed. Eng."],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Schizophrenia is a complex and chronic psychiatric disorder that significantly impacts patients\u2019 quality of life. Ranking 12th among 310 diseases and injuries that result in disability, the number of patients suffering from schizophrenia continues to rise, emphasizing the urgent need for developing effective treatments. Despite the availability of effective antipsychotic drugs, over 80% of patients taking oral antipsychotics experience relapses, primarily caused by non-adherence as the high dosing frequency is required. In this review, we discuss about schizophrenia, its incidence, pathological causes, influencing factors, and the challenges of the current medications. Specifically, we explore nanocrystal technology and its application to paliperidone, making it one of the most successful long-acting antipsychotic drugs introduced to the market. We highlight the clinical advantages of paliperidone nanocrystals, including improved adherence, efficacy, long-term outcomes, patient satisfaction, safety, and cost-effectiveness. Additionally, we address the physicochemical factors influencing the drug\u2019s half-life, which crucially contribute to long-acting medications. Further studies on nanocrystal-based long-acting medications are crucial for enhancing their effectiveness and reliability. The successful development of paliperidone nanocrystals holds great promise as a significant approach for drug development, with potential applications for other chronic disease management.<\/jats:p>","DOI":"10.1088\/2516-1091\/ad8fe7","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T22:54:53Z","timestamp":1731020093000},"page":"012002","update-policy":"https:\/\/doi.org\/10.1088\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The development of paliperidone nanocrystals for the treatment of schizophrenia"],"prefix":"10.1088","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3728-7614","authenticated-orcid":true,"given":"Phattalapol","family":"Lhaglham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9976-138X","authenticated-orcid":false,"given":"Luksika","family":"Jiramonai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4793-1705","authenticated-orcid":true,"given":"Xing-Jie","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingchuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5369","authenticated-orcid":true,"given":"Fangzhou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"266","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"prgbad8fe7bib1","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"key":"prgbad8fe7bib2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1741-7015-2-13","article-title":"A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology","volume":"2","author":"McGrath","year":"2004","journal-title":"BMC Med."},{"key":"prgbad8fe7bib3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4001563","article-title":"Phenotype of schizophrenia: a review and formulation","volume":"10","author":"Tamminga","year":"2005","journal-title":"Mol. Psychiatry"},{"key":"prgbad8fe7bib4","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1177\/107839039800400407","article-title":"The role of serotonin and dopamine in schizophrenia","volume":"4","author":"O\u2019Connor","year":"1998","journal-title":"J. Am. Psychiatr. Nurses Assoc."},{"key":"prgbad8fe7bib5","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9730467","article-title":"The role of dopamine and its dysfunction as a consequence of oxidative stress","volume":"2016","author":"Ju\u00e1rez Olgu\u00edn","year":"2016","journal-title":"Oxid Med. Cell Longev."},{"key":"prgbad8fe7bib6","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s40265-014-0343-0","article-title":"Catechol-O-methyltransferase inhibitors in Parkinson\u2019s disease","volume":"75","author":"M\u00fcller","year":"2015","journal-title":"Drugs"},{"key":"prgbad8fe7bib7","doi-asserted-by":"publisher","first-page":"7673","DOI":"10.1073\/pnas.97.14.7673","article-title":"Schizophrenia: more dopamine, more D2 receptors","volume":"97","author":"Seeman","year":"2000","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"prgbad8fe7bib8","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1176\/ajp.148.11.1474","article-title":"Dopamine in schizophrenia: a review and reconceptualization","volume":"148","author":"Davis","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"prgbad8fe7bib9","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.euroneuro.2013.06.005","article-title":"Schizophrenia and dopamine receptors","volume":"23","author":"Seeman","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"prgbad8fe7bib10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"key":"prgbad8fe7bib11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1365-2885.2008.00944.x","article-title":"Serotonin: a review","volume":"31","author":"Mohammad-Zadeh","year":"2008","journal-title":"J. Vet. Pharmacol. Ther."},{"key":"prgbad8fe7bib12","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.2147\/NDT.S263424","article-title":"Serotonin type 6 and 7 receptors as a novel therapeutic target for the treatment of schizophrenia","volume":"16","author":"Tsegay","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"prgbad8fe7bib13","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.4103\/0019-5545.196973","article-title":"Clinical practice guidelines for management of schizophrenia","volume":"59","author":"Grover","year":"2017","journal-title":"Indian J. Psychiatry"},{"key":"prgbad8fe7bib14","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet"},{"key":"prgbad8fe7bib15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/PROM.S42735","article-title":"Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies","volume":"5","author":"Haddad","year":"2014","journal-title":"Patient Relat. Outcome Meas."},{"key":"prgbad8fe7bib16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106220","article-title":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","volume":"57","author":"Flexner","year":"2021","journal-title":"Int. J. Antimicrob Agents"},{"key":"prgbad8fe7bib17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","article-title":"Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors","volume":"30","author":"Valenstein","year":"2004","journal-title":"Schizophr. Bull."},{"key":"prgbad8fe7bib18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.euroneuro.2004.07.003","article-title":"Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets","volume":"15","author":"Chue","year":"2005","journal-title":"Eur. Neuropsychopharmacol."},{"key":"prgbad8fe7bib19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/neurolint13030035","article-title":"Paliperidone to treat psychotic disorders","volume":"13","author":"Minwalla","year":"2021","journal-title":"Neurol. Int."},{"key":"prgbad8fe7bib20","doi-asserted-by":"publisher","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"prgbad8fe7bib21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12888-022-03758-w","article-title":"Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder","volume":"22","author":"Doane","year":"2022","journal-title":"BMC Psychiatry"},{"key":"prgbad8fe7bib22","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1069432","article-title":"Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: what is the evidence?","volume":"13","author":"Vasiliu","year":"2022","journal-title":"Front. Psychiatry"},{"key":"prgbad8fe7bib23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/schbul\/21.4.567","article-title":"Conventional antipsychotic medications for schizophrenia","volume":"21","author":"Dixon","year":"1995","journal-title":"Schizophr. Bull."},{"key":"prgbad8fe7bib24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","article-title":"The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements","volume":"36","author":"Buchanan","year":"2010","journal-title":"Schizophr. Bull."},{"key":"prgbad8fe7bib25","first-page":"18","article-title":"Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics","volume":"64","author":"Ereshefsky","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"prgbad8fe7bib26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","article-title":"Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies","volume":"12","author":"Kane","year":"2013","journal-title":"World Psychiatry"},{"key":"prgbad8fe7bib27","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA"},{"key":"prgbad8fe7bib28","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/sj.npp.1300157","article-title":"Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine","volume":"28","author":"Lieberman","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"prgbad8fe7bib29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3109\/10401230309085668","article-title":"Clozapine: a clinical review of adverse effects and management","volume":"15","author":"Iqbal","year":"2003","journal-title":"Ann. Clin. Psychiatry"},{"key":"prgbad8fe7bib30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3390\/healthcare12030339","article-title":"Third-generation antipsychotics and lurasidone in the treatment of substance-induced psychoses: a narrative review","volume":"12","author":"Ricci","year":"2024","journal-title":"Healthcare"},{"key":"prgbad8fe7bib31","first-page":"42","article-title":"Long-acting injectable paliperidone palmitate: a review of efficacy and safety","volume":"47","author":"Morris","year":"2017","journal-title":"Psychopharmacol. Bull."},{"key":"prgbad8fe7bib32","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2023.114862","article-title":"Long-acting parenteral drug delivery systems for the treatment of chronic diseases","volume":"198","author":"Jindal","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"prgbad8fe7bib33","doi-asserted-by":"publisher","first-page":"3226","DOI":"10.1038\/s41467-022-30902-7","article-title":"Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation","volume":"13","author":"Deodhar","year":"2022","journal-title":"Nat. Commun."},{"key":"prgbad8fe7bib34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.addr.2019.05.003","article-title":"Translational challenges in advancing regenerative therapy for treating neurological disorders using nanotechnology","volume":"148","author":"Nemeth","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"prgbad8fe7bib35","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1016\/j.apsb.2021.05.002","article-title":"A review of existing strategies for designing long-acting parenteral formulations: focus on underlying mechanisms, and future perspectives","volume":"11","author":"Shi","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"prgbad8fe7bib36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.drudis.2018.01.016","article-title":"Pharmaceutical nanocrystals: production by wet milling and applications","volume":"23","author":"Malamatari","year":"2018","journal-title":"Drug Discov. Today"},{"key":"prgbad8fe7bib37","first-page":"437","article-title":"Nanosizing: \u201cEnd-to-end\u201d formulation strategy for poorly water-soluble molecules","author":"Merisko-Liversidge","year":"2015"},{"key":"prgbad8fe7bib38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/1061186X.2017.1419363","article-title":"Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook","volume":"26","author":"Mu","year":"2018","journal-title":"J. Drug Target"},{"key":"prgbad8fe7bib39","doi-asserted-by":"publisher","first-page":"449","DOI":"10.2147\/NDT.S140383","article-title":"Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice","volume":"15","author":"Lopez","year":"2019","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"prgbad8fe7bib40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/87551225231153541","article-title":"Invega Hafyera (paliperidone palmitate): extended-release injectable suspension for patients with schizophrenia","volume":"39","author":"Peters","year":"2023","journal-title":"J. Pharm. Technol."},{"key":"prgbad8fe7bib41","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/14737175.2024.2325655","article-title":"Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults","volume":"24","author":"Cirnigliaro","year":"2024","journal-title":"Expert Rev. Neurother."},{"key":"prgbad8fe7bib42","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ajps.2017.09.005","article-title":"Tablets of paliperidone using compression-coated technology for controlled ascending release","volume":"13","author":"Tang","year":"2018","journal-title":"Asian J. Pharm. Sci."},{"key":"prgbad8fe7bib43","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jconrel.2022.03.012","article-title":"Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes","volume":"345","author":"McGuckin","year":"2022","journal-title":"J Control. Release"},{"key":"prgbad8fe7bib44","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s12274-022-4819-z","article-title":"Modularly engineered prodrug-nanoassemblies for cancer therapy: nonpharmacological moiety dominating delivery fates","volume":"16","author":"Wang","year":"2023","journal-title":"Nano Res."},{"key":"prgbad8fe7bib45","doi-asserted-by":"publisher","first-page":"9092","DOI":"10.1007\/s12274-022-4544-7","article-title":"Boosting SN38-based oral chemotherapy to combine reduction-bioactivated structured lipid-mimetic prodrug with ascorbic acid","volume":"15","author":"Wang","year":"2022","journal-title":"Nano Res."},{"key":"prgbad8fe7bib46","doi-asserted-by":"publisher","first-page":"9215","DOI":"10.1007\/s12274-022-4598-6","article-title":"A prodrug nanoplatform via esterification of STING agonist and IDO inhibitor for synergistic cancer immunotherapy","volume":"15","author":"Syeda","year":"2022","journal-title":"Nano Res."},{"key":"prgbad8fe7bib47","doi-asserted-by":"publisher","first-page":"5491","DOI":"10.1007\/s12274-024-6533-5","article-title":"Balancing efficacy and safety of doxorubicin-loaded albumin nanoparticles utilizing pH-sensitive doxorubicin-fatty acid prodrugs","volume":"47","author":"Yu","year":"2024","journal-title":"Nano Res."},{"key":"prgbad8fe7bib48","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20220008","article-title":"Indocyanine green potentiated paclitaxel nanoprodrugs for imaging and chemotherapy","volume":"2","author":"Xiang","year":"2022","journal-title":"Exploration"},{"key":"prgbad8fe7bib49","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20220141","article-title":"Small-molecule nanoprodrug with high drug loading and EGFR, PI3K\/AKT dual-inhibiting properties for bladder cancer treatment","volume":"3","author":"Li","year":"2023","journal-title":"Exploration"},{"key":"prgbad8fe7bib50","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1038\/s41467-021-23668-x","article-title":"Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir","volume":"12","author":"Gautam","year":"2021","journal-title":"Nat. Commun."},{"key":"prgbad8fe7bib51","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41467-018-02885-x","article-title":"Creation of a long-acting nanoformulated dolutegravir","volume":"9","author":"Sillman","year":"2018","journal-title":"Nat. Commun."},{"key":"prgbad8fe7bib52","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1038\/s41467-021-25690-5","article-title":"Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles","volume":"12","author":"Cobb","year":"2021","journal-title":"Nat. Commun."},{"key":"prgbad8fe7bib53","doi-asserted-by":"publisher","first-page":"22286","DOI":"10.3390\/molecules201219851","article-title":"Understanding critical quality attributes for nanocrystals from preparation to delivery","volume":"20","author":"Peltonen","year":"2015","journal-title":"Molecules"},{"key":"prgbad8fe7bib54","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/17512433.2016.1191945","article-title":"Three-month paliperidone palmitate\u2014a new treatment option for schizophrenia","volume":"9","author":"Bernardo","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"prgbad8fe7bib55","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ijpharm.2014.05.052","article-title":"Development and comparison of intramuscularly long-acting paliperidone palmitate nanosuspensions with different particle size","volume":"472","author":"Leng","year":"2014","journal-title":"Int. J. Pharm."},{"key":"prgbad8fe7bib56","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/mp500070m","article-title":"Making the leap from daily oral dosing to long-acting injectables: lessons from the antipsychotics","volume":"11","author":"Remenar","year":"2014","journal-title":"Mol. Pharm."},{"key":"prgbad8fe7bib57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-022-00771-5","article-title":"Pharmacokinetics of long-acting aqueous nano-\/microsuspensions after intramuscular administration in different animal species and humans-a review","volume":"25","author":"Nguyen","year":"2022","journal-title":"AAP J."},{"key":"prgbad8fe7bib58","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2165\/11316870-000000000-00000","article-title":"Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia","volume":"48","author":"Samtani","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"prgbad8fe7bib59","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1002\/jcph.295","article-title":"A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia","volume":"54","author":"Cleton","year":"2014","journal-title":"J. Clin. Pharmacol."},{"key":"prgbad8fe7bib60","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/cpdd.144","article-title":"Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia","volume":"4","author":"Rossenu","year":"2015","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"prgbad8fe7bib61","author":"Lhaglham","year":"2024"},{"key":"prgbad8fe7bib62","first-page":"443","author":"Thenge","year":"2022"},{"key":"prgbad8fe7bib63","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1007\/s11051-012-0934-1","article-title":"A new nanospray drying method for the preparation of nicergoline pure nanoparticles","volume":"14","author":"Martena","year":"2012","journal-title":"J. Nanopart. Res."},{"key":"prgbad8fe7bib64","first-page":"53","author":"Zhang","year":"2022"},{"key":"prgbad8fe7bib65","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.addr.2011.02.001","article-title":"Physical and chemical stability of drug nanoparticles","volume":"63","author":"Wu","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"prgbad8fe7bib66","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.2174\/1381612824666180524103341","article-title":"Recent trends in nanocrystals for pharmaceutical applications","volume":"24","author":"Sun","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"prgbad8fe7bib67","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.addr.2011.03.011","article-title":"Production methods for nanodrug particles using the bottom-up approach","volume":"63","author":"Chan","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"prgbad8fe7bib68","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1007\/s11095-010-0323-3","article-title":"Bottom-up preparation techniques for nanocrystals of lipophilic drugs","volume":"28","author":"de Waard","year":"2011","journal-title":"Pharm. Res."},{"key":"prgbad8fe7bib69","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.apsb.2015.11.005","article-title":"Injected nanocrystals for targeted drug delivery","volume":"6","author":"Lu","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"prgbad8fe7bib70","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/1567201817666200512104833","article-title":"Drug nanocrystals: a comprehensive review with current regulatory guidelines","volume":"17","author":"Dhaval","year":"2020","journal-title":"Curr. Drug Deliv."},{"key":"prgbad8fe7bib71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120929","article-title":"Formulation, process, and storage strategies for lyophilizates of lipophilic nanoparticulate systems established based on the two models paliperidone palmitate and solid lipid nanoparticles","volume":"606","author":"Trenkenschuh","year":"2021","journal-title":"Int. J. Pharm."},{"key":"prgbad8fe7bib72","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/pharmaceutics14051094","article-title":"Comparison of paliperidone palmitate from different crystallization processes and effect on formulations in vitro and in vivo","volume":"14","author":"Shi","year":"2022","journal-title":"Pharmaceutics"},{"key":"prgbad8fe7bib73","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejpb.2023.06.003","article-title":"Accelerated reactive dissolution model of drug release from long-acting injectable formulations","volume":"189","author":"Sonntag","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"prgbad8fe7bib74","doi-asserted-by":"publisher","first-page":"393","DOI":"10.22159\/ajpcr.2018.v11i4.24964","article-title":"Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of paliperidone using different hydrophilic carriers: in vitro-in vivo study","volume":"11","author":"Rajkumar","year":"2018","journal-title":"Asian J. Pharm. Clin. Res."},{"key":"prgbad8fe7bib75","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/pharmaceutics12020160","article-title":"Long-acting paliperidone parenteral formulations based on polycaprolactone nanoparticles; the influence of stabilizer and chitosan on in vitro release, protein adsorption, and cytotoxicity","volume":"12","author":"Elmowafy","year":"2020","journal-title":"Pharmaceutics"},{"key":"prgbad8fe7bib76","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijpharm.2012.09.034","article-title":"Drug nanocrystals in the commercial pharmaceutical development process","volume":"453","author":"M\u00f6schwitzer","year":"2013","journal-title":"Int. J. Pharm."},{"key":"prgbad8fe7bib77","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijpharm.2010.07.044","article-title":"Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives","volume":"399","author":"Shegokar","year":"2010","journal-title":"Int. J. Pharm."},{"key":"prgbad8fe7bib78","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jconrel.2017.06.003","article-title":"Nanosizing techniques for improving bioavailability of drugs","volume":"260","author":"Al-Kassas","year":"2017","journal-title":"J.Control. Release."},{"key":"prgbad8fe7bib79","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ajps.2014.12.006","article-title":"Overview of milling techniques for improving the solubility of poorly water-soluble drugs","volume":"10","author":"Loh","year":"2015","journal-title":"Asian J. Pharm. Sci."},{"key":"prgbad8fe7bib80","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/2211738507666190405182524","article-title":"Nanocrystalization: an emerging technology to enhance the bioavailability of poorly soluble drugs","volume":"7","author":"Joshi","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"prgbad8fe7bib81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102357","article-title":"The application of freeze-drying as a production method of drug nanocrystals and solid dispersions\u2014A review","volume":"62","author":"Jakubowska","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"prgbad8fe7bib82","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.addr.2010.12.007","article-title":"Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology","volume":"63","author":"Merisko-Liversidge","year":"2011","journal-title":"Adv. Drug Deliv. Rev."},{"key":"prgbad8fe7bib83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0928-0987(02)00251-8","article-title":"Nanosizing: a formulation approach for poorly-water-soluble compounds","volume":"18","author":"Merisko-Liversidge","year":"2003","journal-title":"Eur. J. Pharm. Sci."},{"key":"prgbad8fe7bib84","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/pharmaceutics16010028","article-title":"Long-Acting Injectable Antipsychotics-A Review on Formulation and In Vitro Dissolution","volume":"16","author":"Markowicz-Piasecka","year":"2023","journal-title":"Pharmaceutics"},{"key":"prgbad8fe7bib85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/colloids2030026","article-title":"Effect of polysorbates on solids wettability and their adsorption properties","volume":"2","author":"Szymczyk","year":"2018","journal-title":"Colloids Interfaces"},{"key":"prgbad8fe7bib86","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40824-020-0184-8","article-title":"Emerging role of nanosuspensions in drug delivery systems","volume":"24","author":"Jacob","year":"2020","journal-title":"Biomater. Res."},{"key":"prgbad8fe7bib87","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ajps.2013.07.011","article-title":"Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing","volume":"8","author":"Toh","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"prgbad8fe7bib88","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41563-020-0674-z","article-title":"A year-long extended release nanoformulated cabotegravir prodrug","volume":"19","author":"Kulkarni","year":"2022","journal-title":"Nat. Mater."},{"key":"prgbad8fe7bib89","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1080\/17425247.2017.1288212","article-title":"Long-acting slow effective release antiretroviral therapy","volume":"14","author":"Edagwa","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"prgbad8fe7bib90","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jconrel.2018.02.003","article-title":"Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation","volume":"275","author":"Kraft","year":"2018","journal-title":"J. Control. Release"},{"key":"prgbad8fe7bib91","doi-asserted-by":"publisher","DOI":"10.1002\/EXP.20210144","article-title":"Tumor hijacks macrophages and microbiota through extracellular vesicles","volume":"2","author":"Jiang","year":"2022","journal-title":"Exploration"},{"key":"prgbad8fe7bib92","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1021\/mp5001247","article-title":"Targeting of injectable drug nanocrystals","volume":"11","author":"Fuhrmann","year":"2014","journal-title":"Mol. Pharm."},{"key":"prgbad8fe7bib93","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ejpb.2015.09.003","article-title":"Multimodal non-linear optical imaging for the investigation of drug nano-\/microcrystal\u2013cell interactions","volume":"96","author":"Darville","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"prgbad8fe7bib94","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1002\/jps.24014","article-title":"Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats","volume":"103","author":"Darville","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"prgbad8fe7bib95","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.drudis.2017.01.003","article-title":"The in vivo fate of nanocrystals","volume":"22","author":"Lu","year":"2017","journal-title":"Drug Discov. Today"},{"key":"prgbad8fe7bib96","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1021\/acs.molpharmaceut.2c00348","article-title":"Microcrystals of ketal-linked paliperidone prodrugs for long-acting antipsychotics","volume":"19","author":"Xu","year":"2022","journal-title":"Mol. Pharm."},{"key":"prgbad8fe7bib97","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1017\/S1092852919000816","article-title":"Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia","volume":"25","author":"Jain","year":"2020","journal-title":"CNS Spectr."},{"key":"prgbad8fe7bib98","doi-asserted-by":"publisher","first-page":"307","DOI":"10.22037\/ijpr.2019.14408.12370","article-title":"Development and comparison of intramuscularly injected long-acting testosterone undecanoate nano-\/microcrystal suspensions with three different particle size","volume":"20","author":"Jia","year":"2021","journal-title":"Iran. J. Pharm. Res."},{"key":"prgbad8fe7bib99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122793","article-title":"Comparison of in vivo behaviors of intramuscularly long-acting celecoxib nanosuspensions with different particle sizes for the postoperative pain treatment","volume":"636","author":"Qin","year":"2023","journal-title":"Int. J. Pharm."},{"key":"prgbad8fe7bib100","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jconrel.2021.12.011","article-title":"Effect of particle size on in vivo performances of long-acting injectable drug suspension","volume":"341","author":"Ho","year":"2022","journal-title":"J Control. Release"},{"key":"prgbad8fe7bib101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.121320","article-title":"Recent advances in drug polymorphs: aspects of pharmaceutical properties and selective crystallization","volume":"611","author":"Shi","year":"2022","journal-title":"Int. J.Pharm."},{"key":"prgbad8fe7bib102","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/J.ENG.2017.03.022","article-title":"Recent developments in the crystallization process: toward the pharmaceutical industry","volume":"3","author":"Gao","year":"2017","journal-title":"Engineering"},{"key":"prgbad8fe7bib103","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40263-020-00779-5","article-title":"Pharmacokinetic characteristics of long-acting injectable antipsychotics for schizophrenia: an overview","volume":"35","author":"Correll","year":"2021","journal-title":"CNS Drugs"},{"key":"prgbad8fe7bib104","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1093\/schbul\/sbaa063","article-title":"Antipsychotic dose in acute schizophrenia: a meta-analysis","volume":"46","author":"Takeuchi","year":"2020","journal-title":"Schizophr. Bull."},{"key":"prgbad8fe7bib105","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"prgbad8fe7bib106","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1097\/JCP.0000000000000610","article-title":"Paliperidone palmitate long-acting injectable given intramuscularly in the deltoid versus the gluteal muscle: are they therapeutically equivalent?","volume":"36","author":"Ravenstijn","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"prgbad8fe7bib107","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1097\/JCP.0000000000000361","article-title":"Paliperidone palmitate long-acting injectable given intramuscularly in the deltoid versus the gluteal muscle: are they therapeutically equivalent?","volume":"35","author":"Yin","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"prgbad8fe7bib108","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/JCP.0000000000000240","article-title":"Prolonged elimination of paliperidone after administration of paliperidone palmitate depot injections","volume":"35","author":"Helland","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"key":"prgbad8fe7bib109","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/pharmaceutics13070935","article-title":"Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics","volume":"13","author":"Toja-Camba","year":"2021","journal-title":"Pharmaceutics"},{"key":"prgbad8fe7bib110","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/cpdd.737","article-title":"Population pharmacokinetics of paliperidone palmitate (once-monthly formulation) in Japanese, Korean, and Taiwanese patients with schizophrenia","volume":"9","author":"Shimizu","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"prgbad8fe7bib111","doi-asserted-by":"publisher","first-page":"7","DOI":"10.12740\/PP\/64581","article-title":"Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia","volume":"51","author":"Jarema","year":"2017","journal-title":"Psychiatry Pol."},{"key":"prgbad8fe7bib112","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":"A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"prgbad8fe7bib113","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41398-022-02286-1","article-title":"Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis","volume":"12","author":"Kishi","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"prgbad8fe7bib114","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.699748","article-title":"Paliperidone 3-month injection for treatment of schizophrenia: a narrative review","volume":"12","author":"Edinoff","year":"2021","journal-title":"Front. Psychiatry"},{"key":"prgbad8fe7bib115","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/DHPS.S339170","article-title":"Cumulative clinical experience of the use of paliperidone palmitate 3-monthly long-acting injection in the treatment of schizophrenia: a critical appraisal","volume":"15","author":"Garc\u00eda-Carmona","year":"2023","journal-title":"Drug Healthcare Patient Saf."},{"key":"prgbad8fe7bib116","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2022.100111","article-title":"Comparative effectiveness of long-acting injectable antipsychotics in a large naturalistic cohort across two European centers: findings from the long-acting injectable antipsychotics collaborative (LAICO) study","volume":"1","author":"Garc\u00eda-Carmona","year":"2022","journal-title":"Neurosci. Appl."},{"key":"prgbad8fe7bib117","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jpsychires.2022.01.044","article-title":"Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort\u2014A five-year mirror image study","volume":"148","author":"Wallman","year":"2022","journal-title":"J. Psychiatry Res."},{"key":"prgbad8fe7bib118","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/jcm10071408","article-title":"Paliperidone palmitate every three months (PP3M) 2-year treatment compliance, effectiveness and satisfaction compared with paliperidone palmitate-monthly (PP1M) in people with severe schizophrenia","volume":"10","author":"Fern\u00e1ndez-Miranda","year":"2021","journal-title":"J. Clin. Med."},{"key":"prgbad8fe7bib119","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12888-022-03685-w","article-title":"The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach","volume":"22","author":"Correll","year":"2022","journal-title":"BMC Psychiatry"},{"key":"prgbad8fe7bib120","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22m14458","article-title":"The economic burden of schizophrenia in the United States","volume":"83","author":"Kadakia","year":"2022","journal-title":"J. Clin. Psychiatry"},{"key":"prgbad8fe7bib121","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.eurpsy.2017.10.008","article-title":"Direct healthcare cost of schizophrenia\u2014European overview","volume":"48","author":"Kov\u00e1cs","year":"2018","journal-title":"Eur. Psychiatry"},{"key":"prgbad8fe7bib122","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/13696998.2017.1351370","article-title":"Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain","volume":"20","author":"Einarson","year":"2017","journal-title":"J. Med. Econ."},{"key":"prgbad8fe7bib123","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1080\/13696998.2016.1184156","article-title":"Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal","volume":"19","author":"Einarson","year":"2016","journal-title":"J. Med. Econ."},{"key":"prgbad8fe7bib124","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/13696998.2017.1363050","article-title":"Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands","volume":"20","author":"Einarson","year":"2017","journal-title":"J. Med. Econ."},{"key":"prgbad8fe7bib125","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"prgbad8fe7bib126","doi-asserted-by":"publisher","first-page":"yw018","DOI":"10.1093\/ijnp\/pyw018","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study","volume":"19","author":"Savitz","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"prgbad8fe7bib127","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2147\/NDT.S400342","article-title":"Efficacy and safety of paliperidone palmitate 6-month versus paliperidone palmitate 3-month long-acting injectable in European patients with schizophrenia: a post hoc analysis of a global phase-3 double-blind randomized non-inferiority study","volume":"19","author":"Giron-Hernandez","year":"2023","journal-title":"Neuropsychiatry Dis. Treat."},{"key":"prgbad8fe7bib128","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38","article-title":"Patient medication adherence: measures in daily practice","volume":"26","author":"Jimmy","year":"2011","journal-title":"Oman Med. J."},{"key":"prgbad8fe7bib129","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1177\/10398562221142453","article-title":"Persistence and adherence to second-generation antipsychotic long-acting injectable medications for schizophrenia: a comparative study in the Australian context","volume":"31","author":"Pai","year":"2023","journal-title":"Australas. Psychiatry"},{"key":"prgbad8fe7bib130","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40263-022-00917-1","article-title":"Impact of 3-monthly long-acting injectable paliperidone palmitate in schizophrenia: a retrospective, real-world analysis of population-based health records in Spain","volume":"36","author":"Guti\u00e9rrez-Rojas","year":"2022","journal-title":"CNS Drugs"},{"key":"prgbad8fe7bib131","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/YIC.0000000000000285","article-title":"Long-term effects of paliperidone palmitate on hospital stay and treatment continuation","volume":"34","author":"Pappa","year":"2019","journal-title":"Int. Clin. Psychopharmacol."},{"key":"prgbad8fe7bib132","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320924789","article-title":"Partial compliance with long-acting paliperidone palmitate and impact on hospitalization: a 6-year mirror-image study","volume":"10","author":"Pappa","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"prgbad8fe7bib133","doi-asserted-by":"publisher","first-page":"232","DOI":"10.9740\/mhc.2022.08.232","article-title":"Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners","volume":"12","author":"Schwartz","year":"2022","journal-title":"Mental Health Clin."},{"key":"prgbad8fe7bib134","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4140\/TCP.n.2013.538","article-title":"Evaluation of risk factors associated to prescription of benzodiazepines and its patterns in a cohort of patients from mental health: a real world study in Spain","volume":"51","author":"Simal-Aguado","year":"2021","journal-title":"Psychopharmacol. Bull."},{"key":"prgbad8fe7bib135","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/ijnp\/pyad028","article-title":"Long-term efficacy and safety of paliperidone 6-month formulation: an open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia","volume":"26","author":"Najarian","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"prgbad8fe7bib136","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.4088\/JCP.16m11308","article-title":"Does half-life matter after antipsychotic discontinuation? A relapse comparison in schizophrenia with 3 different formulations of paliperidone","volume":"78","author":"Weiden","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"prgbad8fe7bib137","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.2147\/NDT.S221242","article-title":"Comparison of relapse prevention with 3 different paliperidone formulations in patients with schizophrenia continuing versus discontinuing active antipsychotic treatment: a post-hoc analysis of 3 similarly designed randomized studies","volume":"16","author":"Mathews","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"prgbad8fe7bib138","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/YIC.0000000000000300","article-title":"Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort","volume":"35","author":"Mart\u00ednez-Andr\u00e9s","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"prgbad8fe7bib139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125320981500","article-title":"Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes","volume":"10","author":"Pungor","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"prgbad8fe7bib140","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2147\/PPA.S349460","article-title":"One-month versus three-month formulation of paliperidone palmitate treatment in psychotic disorders: patients\u2019, relatives\u2019, and mental health professionals\u2019 perspectives","volume":"16","author":"Spoelstra","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"prgbad8fe7bib141","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41537-017-0025-5","article-title":"Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies","volume":"3","author":"Gopal","year":"2017","journal-title":"npj Schizophr."},{"key":"prgbad8fe7bib142","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jconrel.2018.12.014","article-title":"Creation of a long-acting rilpivirine prodrug nanoformulation","volume":"294","author":"Hilaire","year":"2019","journal-title":"J. Control. Release"},{"key":"prgbad8fe7bib143","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/blood-2008-04-150789","article-title":"A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages","volume":"113","author":"Xia","year":"2009","journal-title":"Blood"},{"key":"prgbad8fe7bib144","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201604508","article-title":"Drug delivery: a nano-in-nano vector: merging the best of polymeric nanoparticles and drug nanocrystals","volume":"27","author":"Liu","year":"2017","journal-title":"Adv. Funct. Mater."}],"container-title":["Progress in Biomedical Engineering"],"original-title":[],"link":[{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7","content-type":"text\/html","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7\/pdf","content-type":"application\/pdf","content-version":"am","intended-application":"similarity-checking"},{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T15:30:38Z","timestamp":1732116638000},"score":1,"resource":{"primary":{"URL":"https:\/\/iopscience.iop.org\/article\/10.1088\/2516-1091\/ad8fe7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":144,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,11,20]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1088\/2516-1091\/ad8fe7","relation":{},"ISSN":["2516-1091"],"issn-type":[{"value":"2516-1091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,20]]},"assertion":[{"value":"The development of paliperidone nanocrystals for the treatment of schizophrenia","name":"article_title","label":"Article Title"},{"value":"Progress in Biomedical Engineering","name":"journal_title","label":"Journal Title"},{"value":"paper","name":"article_type","label":"Article Type"},{"value":"\u00a9 2024 IOP Publishing Ltd. All rights, including for text and data mining, AI training, and similar technologies, are reserved.","name":"copyright_information","label":"Copyright Information"},{"value":"2024-06-18","name":"date_received","label":"Date Received","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2024-11-07","name":"date_accepted","label":"Date Accepted","group":{"name":"publication_dates","label":"Publication dates"}},{"value":"2024-11-20","name":"date_epub","label":"Online publication date","group":{"name":"publication_dates","label":"Publication dates"}}]}}